Anesthesiology 2018 May;128(5):953-966
From the Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology (G.C.), Clinical Safety and Surveillance Staff, Immediate Office, Office of Generic Drugs (J.O.), Division of Anesthesia, Analgesia, and Addiction Products, Office of Drug Evaluation II, Office of New Drugs (M.A.L.), and Office of Surveillance and Epidemiology (G.D.P.), Center for Drug Evaluation and Research; and Office of Public Health Strategy and Analysis (J.X., M.C.), and Economics Staff, Office of Planning, Office of Policy, Planning, Legislation, and Analysis (K.L.M., C.W.), Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, Maryland. Current position: President, Center for Science in the Public Interest, Washington, D.C. (P.L.). LCDR Chai, CDR Osterhout, and LCDR Liberatore are commissioned officers in the United States Public Health Service (USPHS).